Castle Biosciences, Inc. (CSTL) Q1 2021 Earnings Results

Castle Biosciences, Inc. Beats on EPS, Stock Down 9.18%

Castle Biosciences reported a narrower-than-expected loss per share, beating EPS estimates by 22.73%. However, the stock reacted negatively, declining by 9.18%. This drop may reflect investor concerns about the lack of revenue details and forward guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.17	N/A	+22.73%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Castle Biosciences, Inc. Beats on EPS, Stock Down 9.18%

Key numbers

Management commentary

Castle Biosciences, Inc.

More earnings this week

Castle Biosciences, Inc. Beats on EPS, Stock Down 9.18%

Key numbers

Management commentary